



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2848433 C 2017/01/10

(11)(21) **2 848 433**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(22) **Date de dépôt/Filing Date:** 2004/06/25

(41) **Mise à la disp. pub./Open to Public Insp.:** 2005/01/06

(45) **Date de délivrance/Issue Date:** 2017/01/10

(62) **Demande originale/Original Application:** 2 527 437

(30) **Priorité/Priority:** 2003/06/25 (GB0314943.2)

(51) **Cl.Int./Int.Cl. C12Q 1/48** (2006.01),
C12Q 1/42 (2006.01), **G01N 33/48** (2006.01),
G01N 33/68 (2006.01)

(72) **Inventeurs/Inventors:**
ANDERTON, BRIAN, GB;
HANGER, DIANE, GB;
WARD, MALCOLM, GB;
BYERS, HELEN, GB

(73) **Propriétaires/Owners:**
PROTEOME SCIENCES PLC, GB;
KING'S COLLEGE LONDON, GB

(74) **Agent:** BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.

(54) **Titre : PROCÉDES DE CRIBLAGE**

(54) **Title: SCREENING METHODS**

(57) **Abrégé/Abstract:**

The invention relates to methods of screening compounds capable of inhibiting the activity of fyn in phosphorylating tau at position Y394 or capable of inhibiting the binding of fyn to tau at position Y394. The method involves the step of determining whether the candidate substances have the property of (a) or (b) under conditions in which fyn is capable of (a) or (b) in the absence of the candidate substance.



ABSTRACT

The invention relates to methods of screening compounds capable of inhibiting the activity of fyn in phosphorylating tau at position Y394 or capable of inhibiting the binding of fyn to tau at position Y394. The method involves the step of determining whether the candidates substances have the property of (a) or (b) under conditions in which fyn is capable of (a) or (b) in the absence of the candidate substance.

Screening Methods

Field of the Invention

The present invention relates to methods for screening
5 for substances capable of modulating the phosphorylation
of tau protein, and in particular paired helical filament
(PHF) tau, and the use of such modulators in the
treatment of tauopathies. The assays and screening
methods are based on the identification of new
10 phosphorylation sites in PHF tau and new kinases and
combinations of kinases as therapeutic targets.

Background of the Invention

Alzheimer's disease (AD) is a neurodegenerative disease
15 characterised by the presence of senile plaques and
neurofibrillary tangles in the brain. The degree of
dementia at death correlates better with neurofibrillary
tangle numbers than with senile plaques counts. The
presence of neurofibrillary tangles in neurons results in
20 the death of those neurons, implying that prevention of
tangle formation is an important therapeutic goal. The
principal protein that forms the neurofibrillary tangle
is the microtubule-associated protein, tau, which
assembles into filaments that have the appearance of
25 twisting about each other in pairs and are referred to as
paired helical filaments (PHF). PHF are present in
different locations in degenerating neurons in the
Alzheimer brain and when many aggregate in the neuronal
cell body, they produce the neurofibrillary tangle (Lee
30 et al, 2001).

Senile plaques have an extracellular central deposit of
amyloid β -peptide ($A\beta$), which is surrounded by dystrophic
neurites to form the senile or neuritic plaque. *In vitro*

WO 2005/001114

PCT/GB2004/002739

and *in vivo* A β has been shown to be neurotoxic. A β is derived by proteolytic processing of the larger amyloid precursor protein (APP). Much attention has been focused on A β production as a therapeutic target because its production is believed to be an early event in AD pathogenesis. This is because mutations in the APP gene, which give rise to autosomal dominant AD, result in either increased overall production of A β or in a relative increase in the slightly longer A β_{42} over A β_{40} , the former being more amyloidogenic; A β_{42} has two additional hydrophobic amino acids at the C-terminus of 40-residue A β_{40} thereby endowing the peptide with an increased tendency to aggregate and form amyloid fibres. Mutations in two other genes that also cause autosomal dominant AD, presenilin-1 and presenilin-2 (PS1 & PS2) also result in an increase in the ratio of A β_{42} to A β_{40} . The belief that A β deposition in the brain precedes the appearance of neurofibrillary tangles has been the basis of the amyloid cascade hypothesis but it has been uncertain whether tangles are important in pathogenesis or are only an unimportant epiphenomenon. This has been changed by the discovery of mutations in the gene for tau in some other related neurodegenerative diseases.

The mechanism by which A β kills neurons in the brain has still to be established. Many studies of A β toxicity have been conducted in tissue culture using rat brain neuronal cultures. We have shown that exposure of both foetal rat and human brain neuronal cultures to aggregated A β induces within 2 to 10 minutes increases in the phosphotyrosine content of several proteins but also including tau (Williamson et al 2002). We have also shown that this treatment results in activation of the

WO 2005/001114

PCT/GB2004/002739

tyrosine kinase fyn, a member of the src family of tyrosine kinases. This tyrosine phosphorylation of tau was prevented by inhibitors of the src family of tyrosine kinases.

5

It has previously been reported that increased levels of fyn are associated with neurons containing abnormally phosphorylated tau in AD brain (Shirazi et al, 1993) and we have demonstrated using antibodies that recognise phosphotyrosine that PHF-tau from AD brain contains phosphotyrosine (Williamson et al 2002). We have shown *in vitro* that fyn and Lck, both src family kinases, phosphorylate recombinant human tau and phosphotyrosines 18, 310 and 394 were positively identified in one or more of their respective tryptic peptides, from sequence information of fragmented peptides. In addition, phosphotyrosine at position 197 was inferred from peptide masses in the survey scan (Scales et al, 2002).

20 Intraneuronal deposits of tau in the form of typical neurofibrillary tangles of AD or other morphologically distinct tau aggregates in a number of other neurodegenerative diseases, is the basis for grouping these conditions as tauopathies. Thus, in addition to
25 AD, the main examples of the tauopathies are frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, and multisystem atrophy (MSA). The intracellular tau
30 deposits (usually neuronal but can also be glial) are all filamentous and mostly in a hyperphosphorylated state compared to the level of phosphorylation of tau from control human brain. In the case of AD, this

WO 2005/001114

PCT/GB2004/002739

hyperphosphorylated tau is often referred to as PHF-tau because it is derived from the PHF.

Other than for AD, deposits of A β in the brain are either absent or minimal in these other tauopathies. There are some tauopathy pedigrees with autosomal dominant disease in which the causative gene has been identified as the tau gene and although cases with the same mutation may present with apparently different diseases, they invariably have tau deposits in the brain and are mostly of the FTDP-17 variety. Thus, the finding of mutations in the tau gene which result in disease and deposition of tau aggregates in neurons is compelling evidence for the primary pathogenic importance of tau deposition in all of these conditions, including AD, whatever the primary cause of disease. Therefore, the amyloid cascade hypothesis is borne out by the discovery of tau mutations and confirms that indeed neurofibrillary tangle formation is almost certainly subservient to A β deposition in AD, but that in the other tauopathies lacking A β deposits, then some other primary event must trigger the tau pathology. Tau abnormalities and deposition are therefore important therapeutic targets for all tauopathies, including AD.

Tau is a phosphoprotein, the function of phosphorylation remaining to be unequivocally established. However, increased phosphorylation of tau on multiple serine and threonine residues reduces the ability of tau to promote microtubule assembly and to stabilise assembled microtubules, effects that have been demonstrated both *in vitro* and in cells. Many studies have shown that PHF-tau from AD brain is more heavily phosphorylated on serine and threonine than tau from control brain. This has been

WO 2005/001114

PCT/GB2004/002739

demonstrated partly by protein sequencing and partly by demonstrating that certain monoclonal antibodies only label either PHF-tau or non-phosphorylated tau and not PHF-tau; the epitopes for many of these antibodies have been mapped to particular phosphorylated residues present in PHF-tau and absent from control brain tau. The pathological tau from most other cases of other tauopathies seems to be similarly hyperphosphorylated to PHF-tau.

These findings strongly imply that similar abnormalities in regulating phosphorylation of tau are shared by all the tauopathies including AD. Since phosphorylation of proteins is effected by protein kinases and dephosphorylation by protein phosphatases, identifying the protein kinases and phosphatases for tau is important because they are potentially therapeutic targets for these diseases.

It remains a considerable problem in the art in identifying the enzymes responsible for causing phosphorylation of paired helical filament tau and the sites phosphorylated by those enzymes.

Summary of the Invention

Broadly, the present invention relates to the modulation of the phosphorylation of tau protein through its interaction with kinases and phosphatases. In particular, it is based on the identification of new sites in tau protein that are susceptible to phosphorylation by kinases and to the identification of kinases and combinations of kinases that are capable of phosphorylating new and known phosphorylation sites in tau protein. Importantly, many of the newly identified

WO 2005/001114

PCT/GB2004/002739

sites are present in paired helical filament (PHF) tau, and not in control tau or fetal tau.

5 The present invention is based on the analysis by mass spectrometry PHF-tau and tau from control adult and foetal rat brain, and identifies 12 new sites in PHF-tau, bringing the total to 37 phosphorylation sites (1 site is tyrosine 394 and the other 36 are either serine or threonine residues) and this with >90% sequence coverage.
10 Of these 12 sites, 11 have not been found in tau from normal human brain.

A number of protein kinases have been demonstrated to phosphorylate tau *in vitro*, including glycogen synthase
15 kinase-3 α (GSK-3 α), glycogen synthase kinase-3 β (GSK-3 β), MAP kinases (ERKs 1 & 2), cdk5, cdc2 kinase, JNK, several members of the SAP kinases (1 γ , 2a, 2b, 3, 4), p38MAP kinase, calmodulin-dependent kinase, protein kinase A (PKA), protein kinase C (PKC), casein kinase 1 (CK1),
20 casein kinase 2 (CK2), MARK, PKN, PKB, TTK, DYRK, Rho kinase and phosphorylase kinase. Of these kinases, GSK-3 has been demonstrated to phosphorylate the greatest number of identified sites in PHF-tau, this being 25 sites, including 2 sites that are generated by GSK-3 only
25 when tau is already phosphorylated and PKA phosphorylates 16 sites in PHF-tau. We have now shown also by *in vitro* phosphorylation that CK1 is also a candidate kinase for 6 of the 12 newly identified sites, GSK-3 phosphorylates 4 of these and PKA phosphorylates 2 of the new PHF-tau
30 sites. This brings the total number of sites in PHF-tau that can be phosphorylated by CK1 to 17 sites.

The MAP kinases (ERKs 1 & 2), cdk5, cdc2 kinase, JNK, several members of the SAP kinases (1 γ , 2a, 2b, 3, 4),

WO 2005/001114

PCT/GB2004/002739

and p38MAP kinase are similar in specificity to GSK-3, being essentially proline-directed protein kinases and they all phosphorylate most of the sites phosphorylated by GSK-3. Thus, after these proline-directed protein kinases, CK1 is now the most conspicuous kinase as a candidate for contributing to generating the phosphorylation state of PHF-tau, with only 18 CK1 sites definitely shared by GSK-3. Therefore, of the 36 ser/thr sites in PHF-tau, 31 could potentially be phosphorylated by a combination of GSK-3, CK1, and PKA, and the additional 5 sites remain as orphan sites with no kinase known to phosphorylate these residues. It is possible that GSK-3, CK1 or PKA could phosphorylate some or all of these orphan sites or indeed that one or more of the other potential tau kinases listed above could be responsible and the phosphorylated sites have not been detected. However, the data disclosed herein imply that CK1 should be considered as a strong candidate for generating hyperphosphorylated tau in AD and the other tauopathies and hence is a potential therapeutic target.

Of the known phosphorylation sites in PHF-tau, several are considered to be particularly important. Monoclonal antibody, AT100, of all such antibodies is the most specific for PHF-tau since it does not recognise normal brain tau nor foetal tau; as such it is considered to be diagnostic for pathological hyperphosphorylated tau in the tauopathies. The AT100 epitope requires phosphorylation of both T212 and S214. It is known that T212 and S214 can be phosphorylated by GSK-3 and it has been reported that phosphorylation T212 by GSK-3 primes tau for phosphorylation at S214 by PKA (Singh et al, 1995a,b). We have found that CK1 is also able to

WO 2005/001114

PCT/GB2004/002739

phosphorylate S214, thereby further implicating CK1 in pathological phosphorylation.

One other site in tau, S262, has been shown to be important in regulating the binding of tau to microtubules such that phosphorylation causes dissociation of tau. A novel kinase, MARK, that phosphorylates tau at this site was isolated from brain and proposed as the responsible kinase. We have found that CK1 is also able to phosphorylate S262 and S356, the latter being an homologous residue that may behave like S262 in contributing to regulating binding of tau to microtubules and we have found that both S262 and S356 are phosphorylated in PHF-tau.

Thus, the above two classes of phosphorylation of tau that are considered to be important could be regulated by CK1. Furthermore, it has been reported that CK1, particularly the CK1 δ isoform, is elevated in brain extracts from AD cases compared to controls, which adds to the potential importance of CK1 in pathogenesis (Ghoshal et al, 1999).

With respect to tyrosine phosphorylation, PHF-tau is phosphorylated on tyrosine 394 and fyn is the strongest candidate although other src family kinases may also phosphorylate tau in brain.

Accordingly, in one aspect, the present invention proposes that CK1 is a novel therapeutic target for treating AD and other related tauopathies.

In a further aspect, the present invention proposes that fyn and related src family kinases are novel therapeutic

WO 2005/001114

PCT/GB2004/002739

targets for treating AD and other related tauopathies, in particular for tyrosine phosphorylation sites disclosed herein.

5 In a further aspect, the present invention proposes new phosphorylation sites in tau protein for use in screening for inhibitors of phosphorylation or promoters of dephosphorylation, optionally used in combination with the kinases identified herein as being capable of
10 phosphorylating the sites.

As a consequence of these findings, the new sites and kinases can be used as the basis of assays and assay methods for screening for modulators of the
15 phosphorylation of the sites in tau protein for use or development as therapeutics for the treatment of tauopathies. Preferred modulators are capable of inhibiting the phosphorylation of tau to produce a phosphorylated state similar or identical to that of PHF-
20 tau and/or promoting the dephosphorylation of phosphorylated forms of PHF-tau.

Eleven of the new phosphorylation sites in tau protein are shown in Table 2 in red type in the left hand column.
25 They are the serine and threonine residues at positions S68, T69, T71, (T111/S113), S191, S258, S289, (T414/S416), T427, S433 and S435. A further tyrosine site at position 394 (Y394) has also been identified (e.g. phosphorylated by tyrosine kinases and
30 dephosphorylated by tyrosine phosphatases). Of the 12 sites, 10 are only found in PHF-tau, see Table 2 comparing the PHF tau and control tau columns.

WO 2005/001114

PCT/GB2004/002739

Accordingly, in a further aspect, the present invention provides the use of a tau protein comprising one or more of these phosphorylation sites as defined herein for screening for candidate substances which are capable of inhibiting phosphorylation at the site(s) by a kinase or promoting dephosphorylation of a phosphorylated site by a phosphatase.

In the present invention, the tau protein comprising the phosphorylation sites may be substantially full length and/or wild type tau or PHF-tau protein, or may be a fragment, active portion or sequence variant thereof. In other embodiments, the present invention may employ a corresponding nucleic acid molecule encoding the tau protein. Where a tau protein which is a fragment, active portion or sequence variant is employed, the phosphorylation site(s) may be present with surrounding amino acids from the tau protein sequence. Preferably, the present invention employs PHF-tau protein. In the present invention the numbering of tau and PHF-tau is according to the sequence of the longest brain isoform of human tau (441 amino acids) disclosed in Goedert et al (1989) EMBO J. 1989 Feb;8(2):393-9. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA; or Goedert M, Jakes R. (1990) Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J., 9, 4225-30.

Alternatively or additionally, any of the above defined tau proteins may possess phosphorylation at one or more

WO 2005/001114

PCT/GB2004/002739

of the phosphorylation sites. This enables the effects of cooperative phosphorylation of the protein to be studied, that is, where the phosphorylation of one site is dependent in changes to the tau protein caused by one or more preceding or simultaneous phosphorylation steps. Thus, in some embodiments of the present invention, the tau protein may include one or more of the known tau phosphorylation sites, for example those set out in Table 2, left hand column in black type, in addition to one or more of the newly found sites, and optionally have phosphorylation at one or more of those additional sites.

In a further aspect, the present invention provides a method of screening for substances which are capable of inhibiting phosphorylation at one or more of the site(s) of a tau protein by a kinase, wherein the tau protein comprises one or more phosphorylation sites disclosed herein, the method comprising:

(a) contacting at least one candidate substance, the tau protein as defined herein and a kinase which is capable of phosphorylating the tau protein under conditions in which the kinase is capable of phosphorylating the site(s) of the tau protein in the absence of the candidate substance;

(b) determining whether, and optionally the extent to which, the candidate substance inhibits the phosphorylation of the tau protein at one or more sites of the tau protein; and,

(c) selecting the candidate substance which inhibits phosphorylation of the tau protein at one or more of the sites.

In a further aspect, the present invention provides a method of screening for substances which are capable of

WO 2005/001114

PCT/GB2004/002739

promoting dephosphorylation at one or more of the site(s) of a tau protein by a phosphatase, wherein the tau protein comprises one or more sites as defined herein, the method comprising:

- 5 (a) contacting at least one candidate substance, the tau protein as defined herein and a phosphatase which is capable of dephosphorylating the tau protein under conditions in which the phosphatase is capable of dephosphorylating the site(s) of the tau protein in the
10 absence of the candidate substance;
- (b) determining whether, and optionally the extent to which, the candidate substance promotes the dephosphorylation of the tau protein at one or more sites of the tau protein; and,
- 15 (c) selecting the candidate substance which promotes dephosphorylation of the tau protein at one or more of the sites.

In some embodiments, the method may comprise, having
20 identified a candidate substance according to one of the methods disclosed herein, the further step(s) of optimising the candidate substance to improve one or more of its properties and/or formulating it as a pharmaceutical.

25

In the methods and uses disclosed herein, preferably the kinase is selected from casein kinase 1 (CK1), casein kinase 2 (CK2), protein kinase A (PKA), glycogen synthase kinase 3 α (GSK-3 α), and glycogen synthase kinase 3 β (GSK-
30 3 β). More preferably, the kinase is CK1 or a combination (either simultaneously or sequentially applied) of CK1, PKA and GSK-3 β .

WO 2005/001114

PCT/GB2004/002739

In the present invention, preferably the step of detecting the presence and extent of phosphorylation and dephosphorylation in the tau protein can be carried out using mass spectroscopy as described in detail below.

5 Alternatively, or additionally, site specific recognition agents which are capable of distinguishing between a site which is phosphorylated and one which is not may be used. Examples of such agents known in the art are site specific antibodies such as monoclonal antibody AT100.

10 In a further aspect, the present invention provides a substance obtainable from one of the methods disclosed herein which is capable of inhibiting the phosphorylation or promoting the dephosphorylation of a tau protein at
15 one or more of the above defined sites.

A further aspect of the present invention is based on the finding that casein kinase 1 is capable of phosphorylating a tau protein at previously unknown
20 positions. Some of the positions are known or suspected in the art of being phosphorylation sites, while others are among the phosphorylation sites identified herein for the first time. The sites of PHF-tau protein that are phosphorylated by CK1 include (S46/T50), S113, S131,
25 T149, T169, S184, S208, (S210/T212), S214, S237, S238, S241, S258, S262, T263, S285, S289, S305, S341, S352, S356, T361, T373, T386, (S412/S413/T414/S416 -two of these four), S416, S433 and S435. Of these sites, S113, 184, 208, (210/212), 214, 237, 238, S258, S289, S433 and
30 S435 are disclosed as phosphorylation sites of PHF-tau protein for the first time herein. The sequence of casein kinase 1 is provided in J Biol Chem. 1993 Mar 25;268(9):6394-401. Molecular cloning, expression, and characterization of a 49-kilodalton casein kinase I

WO 2005/001114

PCT/GB2004/002739

isoform from rat testis. Graves PR, Haas DW, Hagedorn CH, DePaoli-Roach AA, Roach PJ.

Accordingly, the present invention provides the use of a
5 casein kinase 1 as defined herein (including fragments,
active portions or sequence variants), or a corresponding
nucleic acid molecule, for screening for candidate
compounds which are capable of (a) inhibiting the
activity of casein kinase 1 in phosphorylating a tau
10 protein such as paired helical filament tau or (b)
binding to casein kinase 1 to inhibit its interaction
with a tau protein such as paired helical filament tau.

In a further aspect, the present invention provides a
15 method of screening for substances which are capable of
inhibiting the phosphorylation of a tau protein by casein
kinase 1 (CK1), wherein the tau protein comprises one or
more phosphorylation sites disclosed herein, the method
comprising:

20 (a) contacting at least one candidate substance,
the tau protein as defined herein and casein kinase 1
under conditions in which the casein kinase 1 is capable
of phosphorylating the site(s) of the tau protein in the
absence of the candidate substance;

25 (b) determining whether, and optionally the extent
to which, the candidate substance inhibits the
phosphorylation of the tau protein at one or more sites
of the tau protein by casein kinase 1; and,

30 (c) selecting the candidate substance which
inhibits phosphorylation of the tau protein at one or
more of the sites.

In a further aspect, the present application also
discloses that a combination of kinases is required to

WO 2005/001114

PCT/GB2004/002739

phosphorylate the majority of the phosphorylation sites disclosed herein or in the prior art. In the experiments disclosed herein, a combination of casein kinase 1 (CK1), protein kinase A (PKA) and glycogen synthase kinase 3 β (GSK-3 β) was found to be capable, either alone or in cooperation, of phosphorylating the majority of the phosphorylation sites of tau protein and in particular PHF-tau protein. This combination of kinases can be used simultaneously or sequentially to screen for modulators of tau phosphorylation, in contrast to prior art proposals that have focussed on screening using a single kinase.

Accordingly, the present invention provides the use of a casein kinase 1 (CK1), protein kinase A (PKA) and glycogen synthase kinase 3 β (GSK-3 β) (including fragments, active portions or sequence variants), or a corresponding nucleic acid molecule, for screening for candidate compounds which are capable of (a) inhibiting the activity of casein kinase 1 in phosphorylating a tau protein or (b) binding to casein kinase 1 to inhibit its interaction with a tau.

In a further aspect, the present invention provides a method of screening for substances which are capable of inhibiting the phosphorylation of a tau protein by casein kinase 1 (CK1), protein kinase A (PKA) and glycogen synthase kinase 3 β (GSK-3 β), wherein the tau protein comprises one or more phosphorylation sites disclosed herein, the method comprising:

(a) contacting at least one candidate substance, the tau protein as defined herein and casein kinase 1 (CK1), protein kinase A (PKA) and glycogen synthase

WO 2005/001114

PCT/GB2004/002739

kinase 3β (GSK- 3β) under conditions in which the kinases are capable of phosphorylating the site(s) of the tau protein in the absence of the candidate substance;

(b) determining whether, and optionally the extent to which, the candidate substance inhibits the phosphorylation of the tau protein at one or more sites of the tau protein by the kinases; and,

(c) selecting the candidate substance which inhibits phosphorylation of the tau protein at one or more of the sites.

In this aspect of the invention, one or more of these kinases may be substituted by a kinase having the same or a similar activity and/or substrate specificity.

Embodiments of the present invention will now be discussed in more detail by way of example and not limitation with reference to the accompanying tables.

Tables

Table 1 summarises the new sites found in the work leading to the present invention and the kinases capable of acting at those sites. Tables 2 and 3 present this data in more detail.

SEQ ID NO: 1 shows the amino acid sequence of rat casein kinase 1, a 428 amino acid protein.

SEQ ID NO: 2 shows the amino acid sequence of the long form of human tau protein, a 441 amino acid protein.

SEQ ID NO: 3 shows the amino acid sequence of human fyn kinase, a 537 amino acid protein.

Detailed DescriptionTau proteins

The assays and assay methods disclosed herein can employ wild-type or full length tau proteins, kinases or phosphatases or fragments, active portions or derivatives thereof. In the case of tau proteins, the materials used in the assays may be unphosphorylated or partially phosphorylated as discussed above.

In the present invention, derivatives of the tau proteins, kinases (especially CK1 kinase or fyn kinase) or phosphatases have an amino acid sequence which differs by one or more amino acid residues from the wild-type amino acid sequence, by one or more of addition, insertion, deletion and substitution of one or more amino acids. Thus, variants, derivatives, alleles, mutants and homologues, e.g. from other organisms, are included. Thus, a derivative of tau protein or CK1 kinase or fyn kinase may include 1, 2, 3, 4, 5, greater than 5, or greater than 10 amino acid alterations such as substitutions with respect to the wild-type sequence.

Preferably, a fragment or derivative of a protein used in the assays disclosed herein preferably shares sequence identity with the corresponding portion of the relevant wild-type sequence of the protein, and preferably has at least about 60%, or 70%, or 75%, or 80%, or 85%, 90% or 95% sequence identity. As is well-understood, identity at the amino acid level is generally in terms of amino acid identity which may be defined and determined by the TBLASTN program, of Altschul et al. (1990) *J. Mol. Biol.* 215: 403-10, which is in standard use in the art.

Identity may be over the full-length of the relevant peptide or over a contiguous sequence of about 5, 10, 15,

WO 2005/001114

PCT/GB2004/002739

20, 25, 30, 35, 50, 75, 100 or more amino acids, compared with the relevant wild-type amino acid sequence.

Alternatively, nucleic acid encoding a fragment or derivative may hybridise to the corresponding wild type

5 nucleic acid under stringent conditions, for example as disclosed in textbooks such as Ausubel, Short Protocols in Molecular Biology, 1992 or Sambrook et al, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor

Laboratory Press, 1989, using a hybridization solution

10 comprising: 5X SSC, 5X Denhardt's reagent, 0.5-1.0% SDS, 100 µg/ml denatured, fragmented salmon sperm DNA, 0.05% sodium pyrophosphate and up to 50% formamide.

Hybridization is carried out at 37-42°C for at least six hours. Following hybridization, filters are washed as

15 follows: (1) 5 minutes at room temperature in 2X SSC and 1% SDS; (2) 15 minutes at room temperature in 2X SSC and 0.1% SDS; (3) 30 minutes-1 hour at 37°C in 1X SSC and 1% SDS; (4) 2 hours at 42-65°C in 1X SSC and 1% SDS, changing the solution every 30 minutes.

20 One common formula for calculating the stringency conditions required to achieve hybridization between nucleic acid molecules of a specified sequence homology is (Sambrook et al., 1989):

25
$$T_m = 81.5^{\circ}\text{C} + 16.6\text{Log} [\text{Na}^+] + 0.41(\% \text{ G+C}) - 0.63 (\% \text{ formamide}) - 600/\#bp \text{ in duplex}$$

30 As an illustration of the above formula, using $[\text{Na}^+] = [0.368]$ and 50% formamide, with GC content of 42% and an average probe size of 200 bases, the T_m is 57°C. The T_m of a DNA duplex decreases by 1 - 1.5°C with every 1% decrease in homology. Thus, targets with greater than about 75% sequence identity would be observed using a hybridization temperature of 42°C. Such a sequence would

WO 2005/001114

PCT/GB2004/002739

be considered substantially homologous to the nucleic acid sequence of the present invention.

Methods of Screening for Inhibitors and Enhancers

5 It is well known that pharmaceutical research leading to the identification of a new drug may involve the screening of very large numbers of candidate substances, both before and even after a lead compound has been found. This is one factor which makes pharmaceutical research very
10 expensive and time-consuming. Means for assisting in the screening process can have considerable commercial importance and utility.

As detailed above, methods of screening for a substance
15 which are inhibitors of phosphorylation of tau protein or promoters of dephosphorylation of tau protein can be carried out by contacting one or more test substances with the tau protein and kinase or phosphatase (as defined herein) in a suitable reaction medium, and determining the
20 presence or extent of phosphorylation of dephosphorylation in the presence and absence of the candidate substance. A difference in activity in the presence and absence of the candidate substance is indicative of a modulating effect.

25 Preliminary assays *in vitro* may be followed by, or run in parallel with, *in vivo* assays.

Of course, the person skilled in the art will design any appropriate control experiments with which to compare
30 results obtained in test assays.

Performance of an assay method according to the present invention may be followed by isolation and/or manufacture and/or use of a compound, substance or molecule which

WO 2005/001114

PCT/GB2004/002739

tests positive for ability to modulate interaction between one of the phosphorylation sites of tau protein (as defined herein) and a kinase (such as CK1 or a combination of CK1, PKA and GSK-3 β) or a phosphatase.

5

The precise format of an assay of the invention may be varied by those of skill in the art using routine skill and knowledge. For example, interaction between substances may be studied *in vitro* by labelling one with a detectable label and bringing it into contact with the other which has been immobilised on a solid support. Suitable detectable labels, especially for peptidyl substances include ³⁵S-methionine which may be incorporated into recombinantly produced peptides and polypeptides. Recombinantly produced peptides and polypeptides may also be expressed as a fusion protein containing an epitope which can be labelled with an antibody.

10

15

20

25

30

The protein which is immobilized on a solid support may be immobilized using an antibody against that protein bound to a solid support or via other technologies which are known *per se*. A preferred *in vitro* interaction may utilise a fusion protein including glutathione-S-transferase (GST). This may be immobilized on glutathione agarose beads. In an *in vitro* assay format of the type described above a test compound can be assayed by determining its ability to diminish the amount of labelled peptide or polypeptide which binds to the immobilized GST-fusion polypeptide. This may be determined by fractionating the glutathione-agarose beads by SDS-polyacrylamide gel electrophoresis. Alternatively, the beads may be rinsed to remove unbound protein and the amount of protein which has bound can be

WO 2005/001114

PCT/GB2004/002739

determined by counting the amount of label present in, for example, a suitable scintillation counter.

5 The amount of a candidate substance which may be added to an assay of the invention will normally be determined by trial and error depending upon the type of compound used. Typically, from about 0.001 nM to 1mM or more concentrations of putative inhibitor compound may be used, for example from 0.01 nM to 100µM, e.g. 0.1 to 50
10 µM, such as about 10 µM. Greater concentrations may be used when a peptide is the test substance. Even a molecule which has a weak effect may be a useful lead compound for further investigation and development.

15 Combinatorial library technology provides an efficient way of testing a potentially vast number of different substances for ability to modulate activity of a polypeptide. Such libraries and their use are known in the art. Compounds which may be used may be natural or
20 synthetic chemical compounds used in drug screening programmes. Extracts of plants which contain several characterised or uncharacterised components may also be used.

25 Antibodies directed to the site of interaction in either protein form a further class of putative inhibitor compounds. Candidate inhibitor antibodies may be characterised and their binding regions determined to provide single chain antibodies and fragments thereof
30 which are responsible for disrupting the interaction. Antibodies may also be employed as site specific recognition agents for determining whether phosphorylation of a site in tau protein has occurred during an assay.

WO 2005/001114

PCT/GB2004/002739

Antibodies may be obtained using techniques which are standard in the art. Methods of producing antibodies include immunising a mammal (e.g. mouse, rat, rabbit, horse, goat, sheep or monkey) with the protein or a fragment thereof. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and screened, preferably using binding of antibody to antigen of interest. For instance, Western blotting techniques or immunoprecipitation may be used (Armitage et al., 1992, Nature 357: 80-82). Isolation of antibodies and/or antibody-producing cells from an animal may be accompanied by a step of sacrificing the animal.

As an alternative or supplement to immunising a mammal with a peptide, an antibody specific for a protein may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using lambda bacteriophage or filamentous bacteriophage which display functional immunoglobulin binding domains on their surfaces; for instance see WO 92/01047. The library may be naive, that is constructed from sequences obtained from an organism which has not been immunised with any of the proteins (or fragments), or may be one constructed using sequences obtained from an organism which has been exposed to the antigen of interest.

Antibodies according to the present invention may be modified in a number of ways. Indeed the term "antibody" should be construed as covering any binding substance having a binding domain with the required specificity. Thus the invention covers antibody fragments, derivatives, functional equivalents and homologues of

WO 2005/001114

PCT/GB2004/002739

antibodies, including synthetic molecules and molecules whose shape mimicks that of an antibody enabling it to bind an antigen or epitope.

5 Example antibody fragments, capable of binding an antigen or other binding partner are the Fab fragment consisting of the VL, VH, Cl and CH1 domains; the Fd fragment consisting of the VH and CH1 domains; the Fv fragment consisting of the VL and VH domains of a single arm of an
10 antibody; the dAb fragment which consists of a VH domain; isolated CDR regions and F(ab')₂ fragments, a bivalent fragment including two Fab fragments linked by a disulphide bridge at the hinge region. Single chain Fv fragments are also included.

15

A hybridoma producing a monoclonal antibody according to the present invention may be subject to genetic mutation or other changes. It will further be understood by those skilled in the art that a monoclonal antibody can be
20 subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity
25 determining regions (CDRs), of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP 0 184 187 A, GB 2 188 638 A or EP 0 239 400 A. Cloning and expression of chimeric antibodies are
30 described in EP 0 120 694 A and EP 0 125 023 A.

Hybridomas capable of producing antibody with desired binding characteristics are within the scope of the present invention, as are host cells, eukaryotic or

WO 2005/001114

PCT/GB2004/002739

prokaryotic, containing nucleic acid encoding antibodies (including antibody fragments) and capable of their expression. The invention also provides methods of production of the antibodies including growing a cell
5 capable of producing the antibody under conditions in which the antibody is produced, and preferably secreted.

The reactivities of antibodies on a sample may be determined by any appropriate means. Tagging with
10 individual reporter molecules is one possibility. The reporter molecules may directly or indirectly generate detectable, and preferably measurable, signals. The linkage of reporter molecules may be directly or indirectly, covalently, e.g. via a peptide bond or non-
15 covalently. Linkage via a peptide bond may be as a result of recombinant expression of a gene fusion encoding antibody and reporter molecule. The mode of determining binding is not a feature of the present invention and those skilled in the art are able to choose
20 a suitable mode according to their preference and general knowledge.

Mass Spectroscopy

An LC/MS/MS based strategy was used to discover new
25 phosphorylation sites within tau protein isolated from AD brain. So called PHF-tau was initially extracted from a heat-stable preparation of human AD brain material and subsequently further purified by ion exchange chromatography. Having been separated using SDS-PAGE,
30 phospho-peptide mapping was then undertaken. Coomassie stained bands are excised, reduced, alkylated and enzymatically digested using a suite of proteases such as trypsin, chymotrypsin and endoproteinase Asp-N. Resulting peptide mixtures are then analysed by LC/MS/MS

WO 2005/001114

PCT/GB2004/002739

using a Q-TOF micro instrument with peptide separation achieved using a 75 micron ID PepMap reversed phase column with peptides eluted using a gradient of acetonitrile at a flowrate of 200nl/min.

Database searching against bespoke index files is performed utilising the MascotTM algorithm (Matrix Science). All MS/MS spectra relating to phosphopeptides are then subsequently visually verified to check the result.

Tandem MS/MS of peptides may be used to provide sequence information by virtue of the fragment ions produced. Fragmentation occurs generally across the peptide bond leading to a ladder of sequence ions that are diagnostic of the amino acid sequence. The difference between consecutive ions in a series indicates the mass of the amino acid at that position in the peptide. The most common ion types are b and y ions. The C-terminal containing fragments are designated y-ions and the N-terminal containing fragments are designated b-ions (Roepstorff, P., Fohlman, J. J. Biomed. Mass Spectrom. 1984, 11, 601). Peptides created by trypsin proteolysis and ionised by electrospray generally form ions that are doubly charged. This stems from the presence of basic groups within the peptide, namely, the alpha amino group at the N-terminus and the side chain of the C-terminal lysine or arginine. MS/MS spectra of such peptides generally yield a prominent y-type ion series in the high mass end of the spectrum (Bonner, R., Shushan, B. Rapid Commun. Mass Spectrom. 1995, 9, 1067-1076). Ideally, for de novo sequencing purposes, a complete set of complementary b and y ions will ensure a high confidence

WO 2005/001114

PCT/GB2004/002739

level for the proposed peptide sequence. Moreover, if fragment ions representing the complete sequence of the peptide are present, the site of attachment of the phosphate group can be deduced from the position and pattern of these fragment ions. Therefore, it is possible in most instances to discover the exact site of phosphorylation in each phosphopeptide. In some instances we have even found MS/MS spectra to be heterogeneous. Here two (or more) distinct phosphopeptides are represented in the same spectrum. This is because each phosphopeptide form has the same molecule weight and the same number of phosphate groups, but these are attached to different amino acids within the peptide. Therefore, both forms give rise to precursor ions of the same m/z ratio, which are then selected simultaneously by the mass spectrometer during the MS/MS experiment. In such cases, we refer to the phosphopeptides concerned as "regiomers"

Multiplex Assays for Screening Compounds

In drug development it is desirable to develop rapid high throughput assays with simple read out to show whether a compound has an effect on the proposed target. In the case of compounds inhibiting an enzyme function, such as a kinase, it is possible to develop an artificial substrate for the target enzyme that is modified by the enzyme in a way that the level of modification can be readily detected. In the presence of an inhibitory compound, the substrate is not modified and this can also be readily detected.

In the case of inhibitors of tau phosphorylation, it is necessary to monitor the effect of inhibiting specific protein kinases on the phosphorylation status of a large

WO 2005/001114

PCT/GB2004/002739

number of sites. In one aspect, it is possible to prepare artificial substrates corresponding to each of the phosphorylation sites on tau and assess each compound for their ability to inhibit the phosphorylation of each site independent of the other sites. In such a system, each compound would be added to multiple wells each well containing the proposed kinase target, one of the phosphorylation site-specific artificial substrates and a reporter system to show phosphorylation, such as a monoclonal antibody that binds specifically to the substrate in either the phosphorylated or unphosphorylated form, and which antibody is labelled with a fluorescent marker, an enzyme that converts a colour less substrate into a coloured product, or an enzyme that promotes the production of a luminescent signal. In such an assay, it is desirable that the artificial substrate for the target is immobilised on a solid surface such that as part of the assay procedure any unreacted antibody is removed from the system by washing before the result is read. Such assays may be run in microtitre wells of varying formats of typically 96, or more typically 384, or even more typically 1536 wells, or alternatively may be run on a microarray based on a solid support such as glass.

Alternatively, the effect of different kinase inhibitors on the global phosphorylation status of tau may be designed. In such an assay, full length recombinant tau protein carrying no phosphorylations, or one or more desirable phosphorylations may be used as the substrate. Alternatively, a mixture of equal amounts of all of the artificial substrates representing single phosphorylation sites may be used. Each screening assay will determine the effect of compounds on the inhibition of one, two or

WO 2005/001114

PCT/GB2004/002739

more protein kinases with known activity for the phosphorylation of tau. As with the more simple assays described above substrate, target kinase and compound are added to a well of a microtitre plate and incubated with appropriate buffers and other constituents that permit the phosphorylation of substrate in the absence of an inhibitory compound. The phosphorylation status of the substrate may then be determined using a mixture of antibodies or other molecules with specificity for individual phosphorylation sites on tau, wherein such antibodies or other molecules are each labelled with a unique reporter such as a fluorescent dye or compounds with unique spectral properties in infra-red, visible or ultraviolet spectra. After removal of antibodies that remain unbound to the phosphorylated substrate(s), levels of each specific reporter are determined using an appropriate reading device, and the levels of phosphorylation at each specific site in tau is revealed by comparison with a control where no kinase inhibitor was added.

In a preferred embodiment of such a multiplex screening assay, the substrate is dephosphorylated recombinant tau protein and the kinase is selected from CK1, CK2, GSK-3a, GSK-3b, PKA, CDK5, ERK1/2, SAPK1g, SAPK2a, SAPK2b, SAPK3, SAPK4, stress activated protein kinase family kinases (SAPKs) such as p38MAPK and JNK, MARK family kinases such as 110K, cdc2, cdk2, PKC, PKN, TTK, PKB, DYRK, PK, CaMKII, PKD, Rho kinase, or a mixture of one of more these kinases. Reporter systems are preferably labelled antibodies, typically monoclonal antibodies, for example those that can be obtained from rabbits or mice using techniques well known in the art. Labels are preferably fluorescent or colorimetric compounds that are covalently

WO 2005/001114

PCT/GB2004/002739

attached to antibodies, more preferably fluorescent or colorimetric nanoparticles and are most preferably nanoparticles with unique Raman spectra.

5 Development of Mimetic Substances

Other candidate inhibitor compounds may be based on modelling the 3-dimensional structure of a polypeptide or peptide fragment and using rational drug design to provide potential inhibitor compounds with particular
10 molecular shape, size and charge characteristics.

Once candidate substance have been found in the assays and screens according to the present invention, they may be used to design mimetic compounds for development as
15 drugs. The designing of mimetics to a known pharmaceutically active compound is a known approach to the development of pharmaceuticals based on a "lead" compound. This might be desirable where the active compound is difficult or expensive to synthesise or where
20 it is unsuitable for a particular method of administration, e.g. peptides are unsuitable active agents for oral compositions as they tend to be quickly degraded by proteases in the alimentary canal. Mimetic design, synthesis and testing is generally used to avoid
25 randomly screening large number of molecules for a target property.

There are several steps commonly taken in the design of a mimetic from a compound having a given target property.
30 Firstly, the particular parts of the compound that are critical and/or important in determining the target property are determined. In the case of a peptide, this can be done by systematically varying the amino acid residues in the peptide, e.g. by substituting each

WO 2005/001114

PCT/GB2004/002739

residue in turn. These parts or residues constituting the active region of the compound are known as its "pharmacophore".

5 Once the pharmacophore has been found, its structure is modelled to according its physical properties, e.g. stereochemistry, bonding, size and/or charge, using data from a range of sources, eg spectroscopic techniques, X-ray diffraction data and NMR. Computational analysis, 10 similarity mapping (which models the charge and/or volume of a pharmacophore, rather than the bonding between atoms) and other techniques can be used in this modelling process.

15 In a variant of this approach, the three-dimensional structure of the ligand and its binding partner are modelled. This can be especially useful where the ligand and/or binding partner change conformation on binding, allowing the model to take account of this in the design 20 of the mimetic.

A template molecule is then selected onto which chemical groups which mimic the pharmacophore can be grafted. The template molecule and the chemical groups grafted on to 25 it can conveniently be selected so that the mimetic is easy to synthesise, is likely to be pharmacologically acceptable, and does not degrade *in vivo*, while retaining the biological activity of the lead compound. The mimetic or mimetics found by this approach can then be 30 screened to see whether they have the target property, or to what extent they exhibit it. Further optimisation or modification can then be carried out to arrive at one or more final mimetics for *in vivo* or clinical testing.

WO 2005/001114

PCT/GB2004/002739

Pharmaceutical Compositions

Following identification of a substance which modulates or affects phosphorylation or dephosphorylation of tau protein, the substance may be investigated further.

Furthermore, it may be manufactured and/or used in preparation, i.e. manufacture or formulation, of a composition such as a medicament, pharmaceutical composition or drug. These may be administered to individuals.

Thus, the present invention extends in various aspects not only to a substance identified using the screening assays and assay methods disclosed herein, but also a pharmaceutical composition, medicament, drug or other composition comprising such a substance, a method comprising administration of such a composition to a patient, e.g. to treat tauopathies, use of such a substance in manufacture of a composition for administration for the treatment of tauopathies, and a method of making a pharmaceutical composition comprising admixing such a substance with a pharmaceutically acceptable excipient, vehicle or carrier, and optionally other ingredients.

The substances identified as kinase inhibitors or phosphatase promoters in the assays and assay methods of the present invention, or compounds or substances arising from further development or optimisation, may be formulated in pharmaceutical compositions. These compositions may be employed for the treatment of tauopathies, that is conditions which are characterised by neurofibrillary tangles or aggregates of tau protein. Tauopathies are a recognised class of conditions known to those skilled in the art and include Alzheimer's disease,

WO 2005/001114

PCT/GB2004/002739

frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, multisystem atrophy (MSA), neurobasal degeneration with iron accumulation, type 1 (Hallervorden-Spatz), argyrophilic grain dementia, Down's syndrome, diffuse neurofibrillary tangles with calcification, dementia pugilistica, Gerstmann-Sträussler-Scheinker disease, myotonic dystrophy, Niemann-Pick disease type C, progressive subcortical gliosis, prion protein cerebral amyloid angiopathy, tangle only dementia, postencephalitic parkinsonism, subacute sclerosing panencephalitis, Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis/parkinsonism-dementia complex, non-Guamanian motor neuron disease with neurofibrillary tangles/dementia, and Parkinson's disease. The intracellular tau deposits are usually neuronal or glial and are filamentous and generally in a hyperphosphorylated state as compared to the level of phosphorylation in tau from control human brain. In the case of AD, this hyperphosphorylated tau is often referred to a paired helical filament tau (PHF) tau because it is derived from the PHF.

These compositions may comprise, in addition to one of the above substances, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the route of administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant.

5 Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil.

Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

10 For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's

15 Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

Whether it is a polypeptide, antibody, peptide, nucleic acid molecule, small molecule or other pharmaceutically useful compound according to the present invention that is to be given to an individual, administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this

25 being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g.

30

WO 2005/001114

PCT/GB2004/002739

decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins. A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially, dependent upon the condition to be treated.

Materials and Methods

Mass Spectrometry

Data Acquisition

Following SDS-PAGE the gel bands relating to PHF-tau were excised, reduced, alkylated and digested with trypsin. Peptides were extracted from the gel pieces by a series of acetonitrile and aqueous washes. The extract was pooled with the initial supernatant and lyophilised. Each sample was then resuspended in 6 ml of 50mM ammonium bicarbonate and analysed by LC/MS/MS. Chromatographic separations were performed using an Ultimate LCTM system (Dionex, UK). Peptides were resolved by reverse phase chromatography on a 75 mm C18 PepMap column. A gradient of acetonitrile in 0.05% formic acid was delivered to elute the peptides at a flow rate of 200 nl/min. Peptides were ionised by electrospray ionisation using a Z-spray source fitted to a Q-TofmicroTM (Micromass, UK). The instrument was set to run in automated switching mode, selecting precursor ions based on their intensity, for sequencing by collision-induced fragmentation.

WO 2005/001114

PCT/GB2004/002739

Data Analysis

The mass spectral data was processed into peak lists and searched against the full-length sequence of Tau-6 (441 amino acids; mw 45847) using Mascot software (Matrix Science, UK). Phosphorylated peptides were identified by selecting phosphate as a variable modification within the searching parameters. Serine, threonine and tyrosine phosphorylation were all considered. The exact location of the modification within each peptide was determined by the pattern of fragment ions produced (see below for further explanation).

Tandem Mass Spectrometry

To obtain definitive evidence and determine the exact site of phosphorylation, peptides were separated by reversed-phase chromatography and sequenced by tandem MS/MS. In these experiments precursor ions relating to each of the phosphopeptides are individually selected and subjected to collision induced dissociation (CID). Fragment ions so produced are indicative of the sequence of the phosphopeptide and the site of modification is determined by the molecular weight of the relevant fragment ions. Conversely, other potential sites of phosphorylation within particular phosphopeptides can also be ruled out by the presence of other fragment ions within the MS/MS spectrum.

An unexpected observation is that on some occasions it has been possible to pinpoint several discrete forms of phosphopeptides within a single MS/MS spectrum. Here the phosphopeptides each have the same molecular weight (and so are selected simultaneously), but differ in the site(s) of phosphorylation. Thus, the fragment ions observed are effectively a composite representation of

WO 2005/001114

PCT/GB2004/002739

each molecule being analysed.

Purification of PHF-tau from Alzheimer brain

Paired helical filament (PHF) tau was purified from
5 Alzheimer brain as described in (Hanger et al, 1998).
Briefly, brain tissue was homogenised and insoluble PHF-
tau was recovered by differential centrifugation.
Following solubilisation in guanidine and dialysis
against a re-naturing buffer, PHF-tau was purified by
10 anion-exchange and reversed-phase chromatography.

Preparation and purification of recombinant human tau

A plasmid expressing the largest tau isoform (2N4R) was
used to prepare and purify recombinant human tau as
15 described previously (Mulot et al, 1994). Briefly, a
bacterial cell lysate expressing 2N4R tau was heated and
centrifuged to remove heat-labile proteins. The
supernatant was fractionated with ammonium sulphate and
precipitated material was solubilised and dialysed into
20 buffer prior to cation-exchange chromatography. Proteins
were eluted with NaCl and fractions containing tau were
pooled and dialysed against ammonium bicarbonate before
lyophilisation.

25 *In vitro phosphorylation of recombinant tau by serine-
/threonine protein kinases*

Recombinant human tau (40µg/ml) was incubated with 67U/ml
casein kinase 1 (CK1), 67U/ml casein kinase 2 (CK2),
167U/ml cyclic AMP-dependent protein kinase (PKA), 67U/ml
30 glycogen synthase-3β (GSK-3β) or all four kinases in
combination, each at the stated concentration, in the
presence of 3mM ATP for 6h at 30°C. Each kinase was
obtained in a purified recombinant form from New England
Biolabs.

WO 2005/001114

PCT/GB2004/002739

In-gel proteolytic digestion of tau

PHF-tau or *in vitro* phosphorylated tau proteins were separated on 10 % (wt/vol) polyacrylamide gels and stained with colloidal Coomassie Blue G. Protein bands corresponding to tau were excised, carbamidomethylated, and digested with proteolytic enzymes (trypsin or Asp-N). Peptides were extracted from gel pieces by a series of acetonitrile and aqueous washes, dried and resuspended in 50mM ammonium bicarbonate.

Amyloid beta treatment of neurons

Rat and human cortical neurons were treated with A β peptide (25-35) or reverse A β peptide (35-25) for 1-10 min. Proteins containing phosphotyrosine were immunoprecipitated and separated by SDS-PAGE. Western blots of heat-stable extracts of neuronal cultures and immunoprecipitates were probed with antibodies to tau.

Results*New sites found in PHF-tau*

Current literature reports 25 known phosphorylation sites (all are serine or threonine) identified by direct means in PHF-tau (Hanger et al, 1998). There are a further 2-3 sites that have been identified by antibody reactivity only. We have found an additional 12 phosphorylation sites in PHF-tau, one of which is a tyrosine residue (tyr394), bringing the total number of sites to 37. Four of the new sites are more amino terminal in tau than any previously reported sites and three sites are more carboxy terminal than found previously. Of the 12 new sites, 4 are present in alternatively-spliced regions of tau and therefore are present only in specific tau isoforms, all previously identified PHF-tau

WO 2005/001114

PCT/GB2004/002739

phosphorylation sites are present in all tau isoforms. Only one of the 12 new sites in PHF-tau (either thr414 or ser416) is detected in tau from normal brain (ser416).

5 *New sites on recombinant tau for each of the 4
serine/threonine kinases investigated*
See also Table 1

10 CK1 found 28 new sites making a total of 30 sites
in all.

17 CK1 sites are present in PHF-tau, including 15 of the new CK1 sites. CK1 is a candidate kinase for 6 of the 12 new PHF-tau sites.

15 CK2 found 5 new sites making a total of 8 in all.
5 CK2 sites are present in PHF-tau, including 3 of the new CK2 sites. CK2 is a candidate kinase for 1 of the 12 new PHF-tau sites

20 GSK-3 found 12 new sites making a total of 38 in all.
21 GSK-3 sites are present in PHF-tau, including 5 of the new GSK-3 β sites. GSK-3 is a candidate kinase for 4 of the 12 new PHF-tau sites

25 PKA found 5 new sites making a total of 24 in all.
16 PKA sites are present in PHF-tau, including 4 of the new PKA sites. PKA is a candidate kinase for 2 of the 12 new PHF-tau sites

30 Comparing PHF-tau phosphorylation sites with the recombinant tau and kinase data, when all of the phosphorylation sites for CK1, GSK-3 β , and PKA are combined, 30-33 of the 37 PHF-tau sites are phosphorylated (3 sites are defined only as one of two

WO 2005/001114

PCT/GB2004/002739

adjacent residues). Of the residual 4 to 7 sites, one is a tyrosine residue that requires tyrosine kinase activity, 4 other sites have no known kinase and the remaining 2 sites are each contained within regions where only 1 of 2 nearby residues are phosphorylated (T111 and S185).

Seven of the 12 new phosphorylation sites in PHF-tau could be generated by CK1, GSK-3, or PKA, four have no known kinase and the fifth site required a tyrosine kinase for phosphorylation.

Combining the four kinases together in a single reaction, we generated one site (thr111) that was not detected with any of the four kinases alone, this residue is not phosphorylated by any other known kinase *in vitro*. Phosphorylation at this residue is also present in PHF-tau. These results show that combinations of kinases can result in phosphorylation at new sites, possibly due to conformational changes induced by the primary phosphorylation step that increase the likelihood of the secondary phosphorylation, possibly by a second enzyme.

Amyloid beta treatment of neurons

We found that treatment of neurons with A β peptide increased tyrosine phosphorylation of neuronal proteins including tau. The increase in phosphotyrosine induced by A β was approximately four times the basal level in tau.

Future experiments

Identify phosphorylation sites of other individual and combinations of protein kinases to emulate PHF-tau phosphorylation *in vitro*. Kinases that have been

WO 2005/001114

PCT/GB2004/002739

implicated in tauopathies include GSK-3 α , ERKs 1 & 2, cdk5, cdc2 kinase, JNK, several members of the SAP kinase family (1 γ , 2a, 2b, 3, 4), p38MAP kinase, calmodulin-dependent kinase, PKC, MARK, PKN, PKB, TTK, DYRK, Rho kinase and phosphorylase kinase.

Determine if phosphorylation of tau with these kinases and other tyrosine kinases induces tau aggregation *in vitro* and in cells. This will allow us to identify the phosphorylation sites that are critical for tau aggregation.

Investigate the effects of specific protein kinase inhibitors, alone and in combination, on tau aggregation in an *in vitro* or cellular context.

Generate transgenic mice (inducibly) expressing CK1 and determine if this model shows cerebral tau deposition. Cross this mouse with other mice expressing candidate kinases (eg a GSK-3 mouse already exists) and examine the rate of tangle formation.

We have recently found (unpublished) that tyr394 is phosphorylated in AD and in foetal tau and have reported that this same residue is phosphorylated by both Fyn and Lck *in vitro*. Fyn has been shown previously to phosphorylate tau and Fyn is increased in a sub-set of neurons in AD. It is also known that A β treatment of neurons induces tau phosphorylation and that Fyn knock-out mice are resistant to A β .

WO 2005/001114

PCT/GB2004/002739

We will treat neurons from wild-type, Fyn knock-out and Src knock-out mice with A β and identify the phosphorylation sites on tau in each case.

5 It is possible that other tyrosine kinases are involved in tau phosphorylation and aggregation and these include those associated with growth factor and neurotrophic factor receptors. Other tyrosine kinase families may also be involved, including Syk kinase, which has been
10 show to phosphorylate another protein (α -synuclein) implicated in neurodegenerative disease in a manner that increases its propensity to aggregate *in vitro*. In each case, we will investigate the effects of phosphorylation on tau aggregation and the effects of kinase inhibition
15 on tau aggregation.

20

WO 2005/001114

PCT/GB2004/002739

Table 1: New sites identified in tau as phosphorylated by individual serine/threonine kinases

Kinase	New sites identified in recombinant tau	New sites present in PHF-tau	Kinase sites present in 12 new PHF-tau sites
CK1	(46/50), 113, 131, 149, 169, 184, 208, (210, 212), 214, 237, 238, 241, 258, 262, 263, 285, 289, 305, 341, 352, 356, 361, 373, 386, (412/413/414/416, 2 sites), 416, 433, 435	113, 184, 208, (210, 212), 214, 237, 238, 258, 262, 289, 356, (412/413/414/416, 2 sites), 416, 433, 435	(111/113), 258, 289, 416, 433, 435 (412/413/414/416, 2 sites)
CK2	(52/56), 199, 386, 400, (412/413/414/416, 1 site)	199, 400, (412/413/414/416, 1 site)	(412/413/414/416, 1 site)
GSK-3	149, 220, 237, 241, 245, 258, 285, 289, 305, 352, 373, (409/412/413/414/416, 2 sites of which 1 or 2 are new)	237, 258, 289, (409/412/413/414/416, 2 sites of which 1 or 2 are new)	258, 289, (409/412/413/414/416, 2 sites of which 1 or 2 are new) 69 (this site is already known for GSK, but is new in PHF-tau)
PKA	210, (217/220), 258, 352, (412/413)	210, (217/220), 258, (412/413)	258, 416

The 12 new sites in PHF-tau are:

68, 69, 71, (111/113), 191, 258, 289, Y394, (414/416),
427, 433, 435

Table 2

Site	PHF-tau	Kinase Mix	CK1	CK2	GSK-3 β	PKA	Site
T17							T17
Y18	A						Y18
Y29							Y29
T30							T30
T39				*			T39
S46	A		$\frac{1}{2}$ N		*		S46
T50			$\frac{1}{2}$ N		*		T50
T52				$\frac{1}{2}$ N			T52
S56				$\frac{1}{2}$ N			S56
S61							S61
S64							S64
S68	*						S68
T69	*				*		T69
T71	*						T71
T76							T76
T95							T95
T101							T101
T102							T102
T111	$\frac{1}{2}$	*					T111
S113	$\frac{1}{2}$	*	*N				S113
T123	?						T123
S129							S129
S131			*N				S131
T135							T135
S137	?						S137
T149		*	*N		*N		T149
T153	A?				*		T153
T169			*N				T169
T175	*	*			*		T175
T181	*	*			*		T181
S184	$\frac{1}{2}$		*N		*		S184
S185	$\frac{1}{2}$						S185
S191	*						S191
S195					*	*	S195
Y197							Y197
S198	*				*	*	S198
S199	*			*N	*	*	S199
S202	*				*	*	S202
T205	A				*	*	T205
S208	*		*N		(*)		S208
S210	*	* $\frac{1}{2}$	$\frac{1}{2}$ N		$\frac{1}{2}$	*N	S210
T212	*	$\frac{1}{2}$	$\frac{1}{2}$ N		* $\frac{1}{2}$	*	T212
S214	*	*	*N		*	*	S214
T217	*	*			*	$\frac{1}{2}$ N	T217
T220	?				*N	$\frac{1}{2}$ N	T220
T231	*	*			*	*	T231
S235	*	$\frac{2}{3}$			*	*	S235
S237	*	$\frac{2}{3}$	*N		*N		S237
S238	*	$\frac{2}{3}$	*N				S238
S241			*N		*N		S241
T245					*N	*	T245

<i>S258</i>	*	*	*N		*N	*N	<i>S258</i>
S262	*	*	*N		*	*	S262
T263		*	*N				T263
S285			*N		*N		S285
<i>S289</i>	*	*	*N		*N		<i>S289</i>
S293						*	S293
S305		*	*N		*N	*	S305
Y310							Y310
S316							S316
T319							T319
S320						*	S320
S324		*			*	*	S324
S341			*N				S341
S352		*	*N		*N	*N	S352
S356	*	*	*N		*	*	S356
T361		*	*N				T361
T373		*	*N		*N		T373
T377							T377
T386			*N	*N			T386
<i>Y394</i>	*						<i>Y394</i>
S396	*	*	*	*	*		S396
S400	*	*		*N	*		S400
T403	*	½			(*)		T403
S404	*	½	*	*	*		S404
S409	*	*			^{2/5} N	* ^{3/5}	S409
S412	*	^{2/4}	^{2/4} N	^{1/4} N	^{2/5} N	^{1/2} N ^{3/5}	S412
S413	*	^{2/4}	^{2/4} N	^{1/4} N	* ^{2/5} N	^{1/2} N ^{3/5}	S413
<i>T414</i>	½	^{2/4}	^{2/4} N	^{1/4} N	^{2/5} N	^{3/5}	<i>T414</i>
<i>S416</i>	½	* ^{2/4}	* ^{2/4} N	^{1/4} N	^{2/5} N	* ^{3/5}	<i>S416</i>
S422	*					*	S422
<i>T427</i>	*						<i>T427</i>
<i>S433</i>	*	½	*N				<i>S433</i>
<i>S435</i>	*	½	*N				<i>S435</i>
Site	PHF-tau	Kinase Mix	CK1	CK2	GSK-3β	PKA	Site

* = identified phosphorylation site

A = identified by antibody labelling; ½ etc = one of two adjacent sites phosphorylated in PHF-tau; ? = suspected sites in PHF-tau

New PHF-tau sites indicated in bold and italics.

Kinase phosphorylation sites

Shaded sites indicate multiple (numbered) phosphorylations at less well-defined sites, N indicates a new site.

Some of the kinase phosphorylation sites were identified using antibodies Kinase sites identified by MS or antibodies are all compiled together in this table

(*) = GSK is phosphorylated on these sites after priming at other sites

Table 3

Site	PHF-tau	No known kinase	CK1 GSK-3 PKA	Mix of 4 kinases	CK1	CK2	GSK-3 β	PKA	Control tau	PHF-tau	Site
S68	*	*									S68
T69	*		*							*	T69
T71	*	*					*			*	T71
T111	1/2			*						*	T111
S113	1/2		*	*	*N					1/2	S113
T175	*		*	*						1/2	T175
T181	*		*	*			*			*	T181
S184	1/2		*		*N		*		*	*	S184
S185	1/2									1/2	S185
S191	*	*								1/2	S191
S198	*		*							*	S198
S199	*		*				*	*	*	*	S199
S202	*		*			*N	*	*	*	*	S202
S208	*		*				*	*	*	*	S208
S210	*		*	* 1/2	1/2N		(*)			*	S210
T212	*		*	1/2	1/2N		1/2	*N		*	T212
S214	*		*	*	*N		* 1/2	*	*	*	S214
T217	*		*	*			*	*		*	T217
T231	*		*	*			*	1/2N	*	*	T231
S235	*		*	2/3			*	*	*	*	S235
S237	*		*	2/3	*N		*	*	*	*	S237
S238	*		*	2/3	*N		*N			*	S238
S258	*		*	*	*N					*	S258
S262	*		*	*	*N		*N	*N		*	S262
S289	*		*	*	*N		*	*		*	S289
S356	*		*	*	*N		*N			*	S356
Y394	?	*					*	*		*	Y394
S396	*		*	*	*	*				?	S396
S400	*		*	*		*N	*		*	*	S400
T403	*		*	1/2					*	*	T403
S404	*		*	1/2	*	*	(*)			*	S404
S409	*		*	*			*		*	*	S409
S412	*	*	(*)	2/4	2/4N	1/4N	2/5N	* 3/5		*	S412
S413	*		*	2/4	2/4N	1/4N	2/5N	1/2N 3/5	3/4	*	S413
T414	1/2	*	(*)	2/4	2/4N	1/4N	* 2/5N	1/2N 3/5	3/4	*	T414
S416	1/2		*	* 2/4	* 2/4N	1/4N	2/5N	3/5	3/4	1/2	S416
S422	*		*				2/5N	* 3/5	* 3/4	*	S422
T427	*	*						*		*	T427
S433	*		*	1/2	*N					*	S433
S435	*		*	1/2	*N					*	S435
Site	PHF-tau	No known kinase	CK1 GSK-3 PKA	Mix of 4 kinases	CK1	CK2	GSK-3 β	PKA	Control tau	PHF-tau	Site

References

- 5 Ghoshal N, Smiley JF, DeMaggio AJ, Hoekstra MF, Cochran EJ, Binder LI, Kuret J. (1999) A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease. *Am J Pathol.* 155, 1163-72.
- 10 Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH. (1998) New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. *J Neurochem.* 71, 2465-76.
- 15 Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.E., Rozovsky, I., Trommer, B., Viola, K.L., Wals, P., Zhang, C., Finch, C.E., Krafft, G.A., and Klein, W.L. (1998). Diffusible, nonfibrillar ligands derived from A β ₁₋₄₂ are potent central nervous system neurotoxins. *Proc. Natl. Acad. Sci. USA* 95, 6448-6453.
- 20 Lee VM, Goedert M, Trojanowski JQ. (2001) Neurodegenerative tauopathies. *Annu Rev Neurosci.* 24, 1121-59.
- 25 Mulot SF, Hughes K, Woodgett JR, Anderton BH, Hanger DP. (1994) PHF-tau from Alzheimer's brain comprises four species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain tau by glycogen synthase kinase-3 beta. *FEBS Lett.* 349, 359-64.
- 30

Scales, TME, Williamson, R., Anderton, BH, Renolds, CH et al (2002) Tyrosine phosphorylation of specific sites on tau by Src family kinases. Neurobiol Aging 23, S500-501.

5 Shirazi, S.K. and Wood, J.G. (1993). The protein tyrosine kinase, fyn, in Alzheimer's disease pathology. Neuroreport 4, 435-437.

10 Singh TJ, Zaidi T, Grundke-Iqbal I, Iqbal K. (1995a) Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline-dependent protein kinases. FEBS Lett. 358, 4-8.

15 Singh TJ, Haque N, Grundke-Iqbal I, Iqbal K. (1995b) Rapid Alzheimer-like phosphorylation of tau by the synergistic actions of non-proline-dependent protein kinases and GSK-3. FEBS Lett. 358, 267-72.

20 Williamson, R., Scales, T., Clark, B.R., Gibb, G., Reynolds, C.H., Kellie, S., Bird, I.N., Varndell, I.M., Sheppard, P.W., Everall, I., and Anderton, B.H. (2002). Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid- β peptide exposure: involvement of Src family
25 protein kinases. J. Neurosci. 22, 10-20.

Claims:

1. A method of screening for candidate substances which
5 are capable of (a) inhibiting the activity of fyn in
phosphorylating a tau protein at a position corresponding
to Y394 or (b) binding to fyn to inhibit its interaction
with a tau protein at Y394, the method comprising the
step of determining whether the candidates substances
10 have the property of (a) or (b) under conditions in which
fyn is capable of (a) or (b) in the absence of the
candidate substance.

2. The method of claim 1 comprising the steps of:
15 (a) contacting at least one candidate substance,
the tau protein and fyn under conditions in which the fyn
is capable of phosphorylating position Y394 of the tau
protein in the absence of the candidate substance;
(b) determining whether the candidate substance
20 inhibits the phosphorylation of the tau protein at
position Y394 of the tau protein by fyn; and,
(c) selecting the candidate substance which
inhibits phosphorylation of the tau protein at position
Y394.

25 3. The method of claim 1 or 2, further comprising
determining the extent to which the candidate substances
have the property of (a) or (b).